Back to search
FDAFDA · Food and drugs·Recall number D-0482-2017

Glipizide 2.5 mg ER Tablets, Manufactured by Watson Laboratories, Inc., Parsippany, NJ 07054, Repackaged by RemedyRepack, Indiana, PA 15701, NDC 52125-0764-02

Published March 1, 2017 · Recall initiated: February 7, 2017

Summary

FDA records drug Class II recall D-0482-2017, published March 1, 2017 and initiated February 7, 2017. Recalling firm: RemedyRepack Inc.; Status: Terminated; Reported quantity: 630 pills (21 bottles x 30 pills per HDPE bottle); Lot: Lot # B0129373-021916; Exp. 10/17 00591-0900-30 Original NDC 52125-0764-02 RemedyRepack NDC. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRepack Inc.
Distributor
Product was distributed to a sold customer in FL.
Lot
Lot # B0129373-021916; Exp. 10/17 00591-0900-30 Original NDC 52125-0764-02 RemedyRepack NDC
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glipizide 2.5 mg ER Tablets, Manufactured by Watson Laboratories, Inc., Parsippany, NJ 07054, Repackaged by RemedyRepack, Indiana, PA 15701, NDC 52125-0764-02 recalled?

Yes. FDA published recall D-0482-2017 on March 1, 2017. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter